12 West Capital Management LP Grows Stake in Maravai LifeSciences Holdings, Inc. $MRVI

Key Points

• 12 West Capital Management LP increased its stake in Maravai LifeSciences by 8.0%, acquiring an additional 930,000 shares, bringing its total holdings to 12,521,335 shares.
• Maravai LifeSciences' stock experienced a decline of 2.1% with a current market price of $2.37, while its price targets from several analysts have been reduced significantly.
• Institutional investors and hedge funds own over 50% of Maravai LifeSciences' stock, indicating strong institutional interest in the company.

12 West Capital Management LP grew its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 8.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 12,521,335 shares of the company's stock after acquiring an additional 930,000 shares during the period. Maravai LifeSciences comprises about 4.1% of 12 West Capital Management LP's portfolio, making the stock its 8th largest holding. 12 West Capital Management LP owned 4.92% of Maravai LifeSciences worth $27,672,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of MRVI. Wells Fargo & Company MN lifted its position in shares of Maravai LifeSciences by 39.8% during the 4th quarter. Wells Fargo & Company MN now owns 52,685 shares of the company's stock valued at $287,000 after acquiring an additional 15,001 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Maravai LifeSciences by 20.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,311,700 shares of the company's stock valued at $7,149,000 after acquiring an additional 221,908 shares during the last quarter. MetLife Investment Management LLC lifted its position in shares of Maravai LifeSciences by 15.7% during the 4th quarter. MetLife Investment Management LLC now owns 74,904 shares of the company's stock valued at $408,000 after acquiring an additional 10,168 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Maravai LifeSciences by 12.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 70,828 shares of the company's stock valued at $387,000 after acquiring an additional 7,946 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Maravai LifeSciences by 5.3% during the 4th quarter. Northern Trust Corp now owns 1,070,425 shares of the company's stock valued at $5,834,000 after acquiring an additional 53,474 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company's stock.

Maravai LifeSciences Stock Up 6.4%

Shares of Maravai LifeSciences stock traded up $0.15 on Friday, hitting $2.51. 1,148,421 shares of the company traded hands, compared to its average volume of 1,142,170. The company has a 50-day moving average price of $2.49 and a 200 day moving average price of $2.36. The company has a quick ratio of 4.49, a current ratio of 5.16 and a debt-to-equity ratio of 0.68. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.66 and a 12-month high of $9.60. The company has a market cap of $640.96 million, a PE ratio of -1.85 and a beta of 0.29.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Royal Bank Of Canada lowered their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 12th. Craig Hallum lowered their price objective on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Robert W. Baird lowered their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Three research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $5.22.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.